Astemizole analogues with reduced hERG inhibition as potent antimalarial compounds

Bioorg Med Chem. 2017 Dec 15;25(24):6332-6344. doi: 10.1016/j.bmc.2017.10.004. Epub 2017 Oct 7.

Abstract

Astemizole is a H1-antagonist endowed with antimalarial activity, but has hERG liabilities. Systematic structural modifications of astemizole led to the discovery of analogues that display very potent activity as inhibitors of the growth of the Plasmodium parasite, but show a decreased hERG inhibition, when compared to astemizole. These compounds can be used as starting point for the development of a new class of antimalarials.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimalarials / chemical synthesis
  • Antimalarials / chemistry
  • Antimalarials / pharmacology*
  • Astemizole / chemical synthesis
  • Astemizole / chemistry
  • Astemizole / pharmacology*
  • Dose-Response Relationship, Drug
  • Humans
  • Molecular Structure
  • Parasitic Sensitivity Tests
  • Plasmodium falciparum / drug effects*
  • Plasmodium falciparum / growth & development
  • Structure-Activity Relationship
  • Transcriptional Regulator ERG / antagonists & inhibitors
  • Transcriptional Regulator ERG / metabolism

Substances

  • Antimalarials
  • ERG protein, human
  • Transcriptional Regulator ERG
  • Astemizole